Nicholas Gross
Overview
Explore the profile of Nicholas Gross including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
174
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frank S, Testa C, Goldstein J, Kayson E, Leavitt B, Oakes D, et al.
CNS Drugs
. 2025 Jan;
39(2):185-195.
PMID: 39825184
Background: Huntington disease (HD) is a progressive neurodegenerative disease that causes psychiatric and neurological symptoms, including involuntary and irregular muscle movements (chorea). Chorea can disrupt activities of daily living, pose...
2.
Hauser R, Barkay H, Fernandez H, Jimenez-Shahed J, Factor S, Gross N, et al.
J Clin Psychopharmacol
. 2024 Jun;
44(4):386-396.
PMID: 38901008
Background: Deutetrabenazine is approved for adults with tardive dyskinesia (TD). Data based on underlying psychiatric condition and baseline dopamine receptor antagonist (DRA) use are limited. Methods: Patients with TD who...
3.
Frank S, Testa C, Edmondson M, Goldstein J, Kayson E, Leavitt B, et al.
CNS Drugs
. 2022 Oct;
36(11):1207-1216.
PMID: 36242718
Background: Deutetrabenazine is approved in the USA, China, Australia, Israel, Brazil, and South Korea for the treatment of chorea associated with Huntington disease. Objective: We aimed to evaluate the long-term...
4.
Kaplan S, Bogojevic D, Rainville C, Gross N
Support Care Cancer
. 2022 Aug;
30(11):9191-9201.
PMID: 36044089
Purpose: Lipegfilgrastim (Lonquex, Teva Pharma B.V.) is approved for reduction in neutropenia duration and febrile neutropenia incidence. In the framework of lipegfilgrastim regulatory approval in the EU, the Health Authorities...
5.
Hauser R, Barkay H, Fernandez H, Factor S, Jimenez-Shahed J, Gross N, et al.
Front Neurol
. 2022 Mar;
13:773999.
PMID: 35280262
Background: Deutetrabenazine is a vesicular monoamine transporter 2 inhibitor approved for the treatment of tardive dyskinesia (TD) in adults. In two 12-week pivotal studies, deutetrabenazine demonstrated statistically significant improvements in...
6.
Sajatovic M, Finkbeiner S, Wilhelm A, Barkay H, Chaijale N, Gross N, et al.
Am J Geriatr Psychiatry
. 2021 Sep;
30(3):360-371.
PMID: 34511333
Objectives: To assess long-term safety and efficacy of deutetrabenazine in younger (<55 years) and older (≥55 years) adult participants with tardive dyskinesia (TD). Design: Three-year, single-arm, open-label extension (OLE) study...
7.
Gordon M, Grachev I, Mazeh I, Dolan Y, Reilmann R, Loupe P, et al.
Digit Biomark
. 2020 Feb;
3(3):103-115.
PMID: 32095771
Previous studies have demonstrated the feasibility and promise of wearable sensors as objective measures of motor impairment in Parkinson disease and essential tremor. However, there are few published studies that...
8.
9.
10.
Baakman A, Zuiker R, van Gerven J, Gross N, Yang R, Fetell M, et al.
Br J Clin Pharmacol
. 2019 Feb;
85(5):970-985.
PMID: 30710391
Aims: In previous studies, the histamine-3 receptor antagonist CEP-26401 had a subtle effect on spatial working memory, with the best effect seen at the lowest dose tested (20 μg), and...